Navigation Links
Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results
Date:8/17/2008

Zevalin(R) net sales of $15 million in 2008 on target; Potential label

expansion could further drive sales

SEATTLE, Aug. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported financial results for the quarter ended June 30, 2008. Total revenues for the quarter were $2.9 million compared to $20,000 for the second quarter of 2007 due primarily to sales of Zevalin(R) (Ibritumomab Tiuxetan), a commercial radiopharmaceutical that CTI acquired in December 2007. Net product sales of Zevalin reached $2.9 million in the second quarter of 2008.

"Given recent sales trends and growing physician interest, as well as recent Congressional action to extend reimbursement rates for Zevalin, we believe we are on track to reach $15 million in annual net sales for Zevalin this year," said James A. Bianco, M.D., CEO of CTI. "Furthermore, potential expansion of the label for Zevalin based upon data we recently obtained from Bayer Schering Pharma's First-line Indolent Trial (FIT) could support future sales growth. In addition to our progress with Zevalin, we now have OPAXIO's Marketing Authorization Application under review in Europe and expect results from our phase III pixantrone trial in the fourth quarter."

Recent Highlights

-- Entered into agreement with Bayer Schering Pharma for access to phase III Zevalin(R) FIT data for potential U.S. supplemental Biologics License Application (sBLA) to seek label expansion.

-- Scheduled meeting with the U.S. Food and Drug Administration (FDA) in September to discuss the possibility of filing a sBLA for use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma based on FIT trial data.

-- Legislation was passed by Congress that would continue the 2007 reimbursement methodology for therapeutic radioimmunotherapies for an additional 18 months with a start date of July
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... of the bacterium Caulobacter crescentus , researchers at the ... production factory, making useful proteins that can act as vaccines ... Society for General Microbiology,s meeting at Heriot-Watt University, Edinburgh, today ... bacterium that has a single protein layer on its surface. ...
... REDWOOD CITY, Calif., Sept. 4 Cardica, Inc. (Nasdaq: ... received a notice from the Listing Qualifications Department of The ... be delisted from NASDAQ based upon NASDAQ staff,s determination that ... stockholders, equity requirement for continued listing on the NASDAQ as ...
... BEIJING, Sept. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... products in China, announced today that,the Ministry of Industry ... issued the initial order to Sinovac to purchase H1N1 ... order, Sinovac is,required to complete the production of 3.3 ...
Cached Biology Technology:Cardica Receives NASDAQ Notification of Non-Compliance 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 3
(Date:4/17/2014)... A new modeling study suggests that fish consumption ... infant exposure to long-lived contaminants like persistent organic ... a team of researchers including University of Toronto ... Wania, looks at how different levels of environmental ... behavior of chemicals in the body influenced exposure ...
(Date:4/17/2014)... Kansas State University engineer has developed a patented ... improvised explosive devices. The same technique could help ... Steven M. and Kay L. Theede chair in ... engineering, and his research team have created a ... in car trunks. The distance detection method ...
(Date:4/17/2014)... Several parasites and pathogens that devastate honeybees in Europe, ... Africa, but do not appear to be impacting native ... team of researchers., The invasive pests include including ... East African honeybees appear to be resilient to these ... used to control pests in Europe, Asia and the ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... PHILADELPHIAThe Academy of Natural Sciences today announced the revival ... an early 19th-century nature magazine of which only 13 complete ... Museum of Nature was published privately in London between 1810 ... one or two color plates. In it, Perry set out ...
... NY) Matthew Levy, Ph.D., assistant professor of biochemistry ... has been awarded more than $700,000 by Stand Up ... Levy,s work will focus on creating self-guiding drugs that ... serious or unpleasant side effects of current therapies. Dr. ...
... Just three months after the Euro 5 Norm ... car models, researchers at the Technische Universitaet Muenchen (TUM) ... meeting the more stringent Euro 6 emissions standard. A ... Chair of Internal Combustion Engines has succeeded in reducing ...
Cached Biology News:The Academy of Natural Sciences and Temple Press revive rare natural history work in new book 2Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3
...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... 178-227 of human YBX2. (Note: ... proprietary). ...
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
... Aminopropylsilane is perhaps the ... chemistry for microarray experiments. ... for Microarrays provide a ... for printing PCR products ...
Biology Products: